These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 12389426)

  • 21. Safety and immunogenicity of a measles, mumps, rubella and varicella vaccine given with combined Haemophilus influenzae type b conjugate/hepatitis B vaccines and combined diphtheria-tetanus-acellular pertussis vaccines.
    Shinefield H; Black S; Thear M; Coury D; Reisinger K; Rothstein E; Xu J; Hartzel J; Evans B; Digilio L; Schödel F; Brown ML; Kuter B;
    Pediatr Infect Dis J; 2006 Apr; 25(4):287-92. PubMed ID: 16567978
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Combined reduced-antigen-content diphtheria-tetanus-acellular pertussis and polio vaccine (dTpa-IPV) for booster vaccination of adults.
    Grimprel E; von Sonnenburg F; Sänger R; Abitbol V; Wolter JM; Schuerman LM
    Vaccine; 2005 May; 23(28):3657-67. PubMed ID: 15882526
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Basic immunization hexvalent vaccine. Are there differences between vaccines?].
    MMW Fortschr Med; 2003 May; 145(19):54. PubMed ID: 12813984
    [No Abstract]   [Full Text] [Related]  

  • 24. Safety and immunogenicity of a hexavalent diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae b conjugate-hepatitis B vaccine at 2, 3, 4, and 12-14 months of age.
    Halperin SA; Tapiero B; Diaz-Mitoma F; Law BJ; Hoffenbach A; Zappacosta PS; Radley D; McCarson BJ; Martin JC; Brackett LE; Boslego JW; Hesley TM; Bhuyan PK; Silber JL
    Vaccine; 2009 Apr; 27(19):2540-7. PubMed ID: 19124057
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Immunogenicity and reactogenicity of a three-dose primary vaccination course with a combined diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated polio-haemophilus influenzae type b vaccine coadministered with a meningococcal C conjugate vaccine.
    Tejedor JC; Omeñaca F; García-Sicilia J; Verdaguer J; Van Esso D; Esporrín C; Molina V; Muro M; Marés J; Enrubia M; Moraga F; García-Corbeira P; Dobbelaere K; Schuerman L;
    Pediatr Infect Dis J; 2004 Dec; 23(12):1109-15. PubMed ID: 15626947
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Safety and immunogenicity of a primary course and booster dose of a combined diphtheria, tetanus, acellular pertussis, hepatitis B and inactivated poliovirus vaccine.
    Meriste S; Lutsar I; Tamm E; Willems P
    Scand J Infect Dis; 2006; 38(5):350-6. PubMed ID: 16709537
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Statement on the recommended use of pentavalent and hexavalent vaccines. An Advisory Committee Statement (ACS).
    National Advisory Committee on Immunization (NACI)
    Can Commun Dis Rep; 2007 Feb; 33(ACS-1):1-14. PubMed ID: 17294559
    [No Abstract]   [Full Text] [Related]  

  • 28. Efficacy trial of acellular pertussis vaccines; trial I.
    Olin P
    Dev Biol Stand; 1997; 89():52-4. PubMed ID: 9333569
    [No Abstract]   [Full Text] [Related]  

  • 29. Italian trial on acellular pertussis vaccines.
    Greco D
    Dev Biol Stand; 1997; 89():55-7. PubMed ID: 9333570
    [No Abstract]   [Full Text] [Related]  

  • 30. Immunogenicity, reactogenicity and safety of a 7-valent pneumococcal conjugate vaccine (PCV7) concurrently administered with a DTPa-HBV-IPV/Hib combination vaccine in healthy infants.
    Knuf M; Habermehl P; Cimino C; Petersen G; Schmitt HJ
    Vaccine; 2006 May; 24(22):4727-36. PubMed ID: 16616973
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Safety, reactogenicity and immunogenicity of a combined hexavalent tetanus, diphtheria, acellular pertussis, hepatitis B, inactivated poliovirus vaccine and Haemophilus influenzae type b conjugate vaccine, for primary immunization of infants.
    Zepp F; Knuf M; Heininger U; Jahn K; Collard A; Habermehl P; Schuerman L; Sänger R
    Vaccine; 2004 Jun; 22(17-18):2226-33. PubMed ID: 15149781
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Diphtheria-tetanus-acellular pertussis and inactivated poliovirus vaccines given separately or combined for booster dosing at 4-6 years of age.
    Black S; Friedland LR; Ensor K; Weston WM; Howe B; Klein NP
    Pediatr Infect Dis J; 2008 Apr; 27(4):341-6. PubMed ID: 18316985
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Quality of the Haemophilus influenzae type b (Hib) antibody response induced by diphtheria-tetanus-acellular pertussis/Hib combination vaccines.
    Denoël PA; Goldblatt D; de Vleeschauwer I; Jacquet JM; Pichichero ME; Poolman JT
    Clin Vaccine Immunol; 2007 Oct; 14(10):1362-9. PubMed ID: 17699836
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Use of combined vaccines in children].
    Plebani A
    Ann Ig; 2002; 14(4 Suppl 5):85-91. PubMed ID: 12389297
    [No Abstract]   [Full Text] [Related]  

  • 35. Immunogenicity of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) when coadministered with different neisseria meningitidis serogroup C conjugate vaccines.
    Wysocki J; Tejedor JC; Grunert D; Konior R; Garcia-Sicilia J; Knuf M; Bernard L; Dieussaert I; Schuerman L
    Pediatr Infect Dis J; 2009 Apr; 28(4 Suppl):S77-88. PubMed ID: 19325450
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Unexplained cases of sudden infant death shortly after hexavalent vaccination.
    Zinka B; Rauch E; Buettner A; Ruëff F; Penning R
    Vaccine; 2006 Jul; 24(31-32):5779-80. PubMed ID: 15908063
    [No Abstract]   [Full Text] [Related]  

  • 37. Societal impact of combination vaccines: experiences of physicians, nurses, and parents.
    Koslap-Petraco MB; Judelsohn RG
    J Pediatr Health Care; 2008; 22(5):300-9. PubMed ID: 18761231
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Laboratory investigation of immune responses to acellular pertussis vaccines when used for boosting adolescents after primary immunisation with whole cell pertussis vaccines: a comparison with data from clinical study.
    Reynolds E; Walker B; Xing D; Southern J; Asokanathan C; Dagg B; Corbel M; Miller E
    Vaccine; 2006 Apr; 24(16):3248-57. PubMed ID: 16480794
    [TBL] [Abstract][Full Text] [Related]  

  • 39. B. Zinka et al., Unexplained cases of sudden infant death shortly after hexavalent vaccination.
    Schmitt HJ; Siegrist CA; Salmaso S; Law B; Booy R
    Vaccine; 2006 Jul; 24(31-32):5781-2; author reply 5785-6. PubMed ID: 16084630
    [No Abstract]   [Full Text] [Related]  

  • 40. Comment on B. Zinka et al., Unexplained cases of sudden infant death shortly after hexavalent vaccination.
    von Kries R
    Vaccine; 2006 Jul; 24(31-32):5783-4; author reply 5785-6. PubMed ID: 16081190
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.